Eli Lilly, a leading pharmaceutical company, has reported impressive financial results for the first three months of 2026, driven largely by high demand for its diabetes and obesity medications. The company’s total revenue for this period reached $19.8 billion, which is a 56% increase compared to the same time last year. This growth has led Lilly to raise its full-year sales forecast to between $82 billion and $85 billion, an increase of $2 billion from their previous estimate.
Two of Lilly’s most popular medications, Mounjaro and Zepbound, played a major role in this success. Mounjaro, used to treat type 2 diabetes, generated $8.7 billion in sales for the quarter, a 125% increase from the first three months of 2025. Zepbound, which helps with weight loss in people with obesity, brought in $4.2 billion, an 80% increase over the same period last year. Despite some challenges in the U.S. related to pricing changes, these drugs continue to perform exceptionally well, showing strong demand from patients and healthcare providers.
Lilly also introduced a new medication in April 2026: Foundayo, a once-daily oral pill for weight loss. This is the company’s first approved oral medication in this category, and it is already available in pharmacies and on more than 12 major telehealth platforms. Early feedback from patients, doctors, and insurance companies has been positive. As of now, over 8,000 healthcare providers have prescribed Foundayo, with one-third of them having no prior experience prescribing oral weight-loss medications. Company executives believe this drug has strong potential due to its ease of use, as it does not require meal restrictions like some other medications.
Lilly is competing in the growing oral obesity treatment market with Novo Nordisk, another major pharmaceutical company that recently launched an oral version of its weight-loss drug, Wegovy. While Wegovy was the first to market, Foundayo is expected to gain a significant share of the market because of its convenience. Analysts from Citi believe that Foundayo’s ease of use will outweigh any minor differences in effectiveness compared to Wegovy.
In addition to its strong drug sales, Lilly has been very active in acquiring other companies and licensing new treatments in 2026. Just recently, Lilly spent $2.3 billion to purchase Ajax Therapeutics, a company focused on blood cancer treatments. This is the sixth major acquisition Lilly has made this year, totaling around $21 billion in spending. The company’s CEO, Dave Ricks, stated that Lilly plans to continue expanding through business deals to strengthen its portfolio of medications.
Overall, Lilly’s strong performance reflects the growing demand for effective treatments in diabetes and obesity, as well as the company’s commitment to innovation and expansion in the healthcare industry.